[1. SARS (Severe Acute Respiratory Syndrome). Available at: https://www.who.int/ith/diseases/sars/en/]Search in Google Scholar
[2. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia. Available at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/]Search in Google Scholar
[3. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: https://covid19.who.int/]Search in Google Scholar
[4. Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395:1015-1018.10.1016/S0140-6736(20)30673-5]Search in Google Scholar
[5. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21.10.1016/S2213-2600(20)30116-8]Search in Google Scholar
[6. Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38:781-782.]Search in Google Scholar
[7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.10.1056/NEJMoa2002032709281932109013]Search in Google Scholar
[8. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020;323:1775-1776.10.1001/jama.2020.468332203977]Search in Google Scholar
[9. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382:e102.10.1056/NEJMoa2007621720693132356626]Search in Google Scholar
[10. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37-55.]Search in Google Scholar
[11. Richardson S, Hirsch JS, Narasimhan M, el al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323:2052-2059.10.1001/jama.2020.6775717762932320003]Search in Google Scholar
[12. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol. 2014;4:1201-1228.10.1002/cphy.c130040413791224944035]Search in Google Scholar
[13. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol. 2005;289:H2281-2290.10.1152/ajpheart.00618.2005720356616055515]Search in Google Scholar
[14. Wang K, Gheblawi M, Oudit GY. Angiotensin Converting Enzyme 2: A Double-Edged Sword. Circulation. 2020. [Epub ahead of print]10.1161/CIRCULATIONAHA.120.04704932213097]Search in Google Scholar
[15. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.10.1016/j.cell.2020.02.052710262732142651]Search in Google Scholar
[16. Matsuyama S, Nagata N, Shirato K, Kuwase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol. 2010;84:12658-12660.10.1128/JVI.01542-10300435120926566]Search in Google Scholar
[17. Bertram S, Heurich A, Lavender H, et al. Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts. PLoSOne. 2012;7:e35876.10.1371/journal.pone.0035876334040022558251]Search in Google Scholar
[18. South, AM, Tomlinson L, Edmonston D, Hiremath S, Sparks MA. Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020;16:305-307.10.1038/s41581-020-0279-4711870332246101]Search in Google Scholar
[19. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-876.10.1038/nm1267709578316007097]Search in Google Scholar
[20. Ocaranza MP, Godoy I, Jalil JE. Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat. Hypertension. 2006;48:572-578.10.1161/01.HYP.0000237862.94083.4516908757]Search in Google Scholar
[21. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor-Dependent Mechanism. Hypertension. 2014;64:1368-1375.10.1161/HYPERTENSIONAHA.114.03743423188325225202]Search in Google Scholar
[22. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.10.1038/nature03712709499816001071]Search in Google Scholar
[23. Crackower M, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822-828.10.1038/nature0078612075344]Search in Google Scholar
[24. Huentelman MJ, Grobe JL, Vazquez J. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790.10.1113/expphysiol.2005.03109616049057]Search in Google Scholar
[25. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970-976.10.1161/01.HYP.0000124667.34652.1a15007027]Search in Google Scholar
[26. Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 1996;14:799-805.10.1097/00004872-199606000-000178793704]Search in Google Scholar
[27. Arendse LB, Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin–angiotensin system and associated peptides in hypertension and heart failure. Pharmacol Rev. 2019;71:539-570.10.1124/pr.118.017129678202331537750]Search in Google Scholar
[28. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.10.1074/jbc.M00261520010924499]Search in Google Scholar
[29. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Resp J. 2008;31:611-617.10.1183/09031936.0016200617959631]Search in Google Scholar
[30. Christopher H, Manaf Z, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Baylor University Medical Center Proceedings. 2018;31:419-423.10.1080/08998280.2018.1499293641400130948970]Search in Google Scholar
[31. Yang G, Tan Z, Zhou L, et al. Angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID-19 patients with hypertension. medRxiv. 2020. [Epub ahead of print]10.1101/2020.03.31.20038935]Search in Google Scholar
[32. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. EmergMicrob Infect. 2020;9:757-760.10.1080/22221751.2020.1746200717036832228222]Search in Google Scholar
[33. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;NEJMoa2006923.10.1056/NEJMoa2006923720693332356627]Search in Google Scholar
[34. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensinaldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020;NEJMoa2008975.10.1056/NEJMoa2008975720693232356628]Search in Google Scholar
[35. Mehta M, Kalra A, Nowacki AS, et al. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;e210855.10.1001/jamacardio.2020.1855720137532936273]Search in Google Scholar
[36. de Abajo FJ, Rodriguez-Martin S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case population study. Lancet. 2020;395:1705-1714.10.1016/S0140-6736(20)31030-8]Search in Google Scholar
[37. Khera R, Clark C, Lu Y, et al. Association of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers with the risk of hospitalization and death in hypertensive patients with Coronavirus Disease-19. medRxiv. 2020;20104943.10.1101/2020.05.17.20104943727324932511481]Search in Google Scholar
[38. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;e200950.10.1001/jamacardio.2020.0950709784132211816]Search in Google Scholar
[39. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061-1069.10.1001/jama.2020.1585704288132031570]Search in Google Scholar
[40. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 13 Mar 2020. Available at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-onhypertension-on-ace-inhibitors-and-ang]Search in Google Scholar
[41. American Heart Association. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. Available at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.]Search in Google Scholar